The Accelerating Access to Critical Therapies (ACT) for ALS Act (signed Dec 2021) is a landmark U.S. law providing $100 million annually (2022–2026) to fund research, speed drug development, and offer expanded access to investigational treatments for ALS patients not eligible for clinical trials. This legislation expires on September 30, 2026, and requires congressional reauthorization to continue.

ACT for ALS gets us closer to a cure by:

• Offering potential therapies and research opportunities for patients who never before had access
• Producing invaluable data on understudied populations that can enable therapies for all ALS patients
• Funding a coordinated research ecosystem that will unlock pathways to treatments, and
• Facilitating critical collection of data and biological samples, and establishing information-sharing platforms